GLP-1 Medications
Mounjaro Dosage: Titration Schedule
Mounjaro (tirzepatide) dosage titration schedule from 2.5mg to 15mg, pen strengths, what happens if you miss a dose, and how to track your escalation.
On this page
Mounjaro (tirzepatide) follows a fixed titration schedule that starts low and increases every four weeks. This isn't optional pacing — it's built into the prescribing protocol because tirzepatide is a potent dual GIP/GLP-1 receptor agonist, and your gastrointestinal system needs time to adapt to each dose level before you move up.
Skipping steps or rushing the titration doesn't get you to results faster. It gets you to nausea, vomiting, and potentially dropping the medication entirely. The schedule exists to keep you on it.
The Titration Schedule
Mounjaro has six dose levels. The first is a starter dose; the remaining five are all approved maintenance doses. Your prescriber determines your target, but the ramp-up pattern is the same for everyone.
| Step | Dose | Duration | Purpose |
|---|---|---|---|
| 1 | 2.5 mg | 4 weeks | Starter dose — GI acclimation only |
| 2 | 5 mg | 4 weeks minimum | First maintenance dose |
| 3 | 7.5 mg | 4 weeks minimum | Intermediate maintenance |
| 4 | 10 mg | 4 weeks minimum | Intermediate maintenance |
| 5 | 12.5 mg | 4 weeks minimum | Higher maintenance |
| 6 | 15 mg | Ongoing | Maximum dose |
2.5 mg (Weeks 1-4): This is not a therapeutic dose. Clinical trials showed minimal weight loss or glycemic effect at 2.5 mg. Its purpose is solely to let your body adjust to the medication's GI effects — slower gastric emptying, altered appetite signaling — before the dose climbs to a level that produces clinical results. Expect mild nausea in this phase. If you don't experience any side effects at 2.5 mg, that doesn't mean the drug isn't working; it means your body is handling the introduction well.
5 mg (Weeks 5-8): The first dose where clinical effects begin to appear. Most people notice appetite suppression becoming more pronounced. GI side effects may intensify temporarily as your system adjusts to the higher level. This is the minimum maintenance dose, and some patients stay here if it's producing adequate results.
7.5 mg (Weeks 9-12): A meaningful step up. In SURMOUNT-1, the 5 mg cohort lost an average of 15% body weight at 72 weeks; the 10 mg cohort lost 19.5%; and the 15 mg cohort lost 22.5%. The intermediate doses (7.5 mg and 12.5 mg) exist to make the jumps between those studied doses more gradual for tolerability.
10 mg (Weeks 13-16): For many patients, this is the dose where the balance between efficacy and tolerability hits its stride. The SURPASS-2 trial showed that tirzepatide 10 mg was superior to semaglutide 1 mg for both HbA1c reduction and weight loss in type 2 diabetes patients.
12.5 mg (Weeks 17-20): Another bridging dose. If 10 mg is producing good results with manageable side effects, your provider may keep you there. If more effect is needed, this step reduces the jump to the maximum.
15 mg (Week 21 onward): The highest approved dose. In clinical trials, this produced the greatest average weight loss and glycemic improvement, but also the highest rates of GI side effects. Not everyone needs or tolerates 15 mg, and that's fine — the dose that works is the dose that you can take consistently.
Pen Strengths and How They Work
Unlike Ozempic, which uses a single pen with an adjustable dose dial, Mounjaro uses fixed-dose, single-use pens. Each pen delivers exactly one dose. There is no dial.
The pens are color-coded by dose:
| Dose | Pen Color | Doses per Box |
|---|---|---|
| 2.5 mg | Light purple (Lilac) | 4 pens |
| 5 mg | Brown (Tan) | 4 pens |
| 7.5 mg | Yellow-green | 4 pens |
| 10 mg | Green (Teal) | 4 pens |
| 12.5 mg | Red (Burgundy) | 4 pens |
| 15 mg | Blue (Navy) | 4 pens |
Each box contains four pens, which is a 4-week supply (one injection per week). When you titrate to a new dose level, your prescriber writes a new prescription for the corresponding pen strength.
Important: You cannot combine pens to make a different dose. Two 2.5 mg pens do not equal one 5 mg pen for pharmacokinetic purposes, and that's not how the medication was studied. Use the pen that matches your prescribed dose.
How to Time Your Weekly Injection
Mounjaro is injected once weekly, on the same day each week. Pick a day that fits your routine — many people choose a day when they'll be home and can manage potential GI effects without disruption.
Changing your injection day: You can shift your day as long as at least 3 days (72 hours) have passed since your last injection. So if you normally inject on Mondays but need to switch to Thursdays, you can make the change in a single week. Just don't inject sooner than 72 hours after your last dose.
Best time of day: There's no pharmacological requirement for a specific time of day. Some people prefer morning injections so any nausea occurs during waking hours when they can manage it. Others prefer evening injections so they sleep through the initial GI effects. Neither is clinically superior — pick what works for you and be consistent.
What Happens If You Miss a Dose
Missed doses happen. Here's the decision framework from the prescribing information:
Less than 4 days (96 hours) since your missed dose was due: Take the injection as soon as you remember. Then resume your regular weekly schedule from that point.
More than 4 days since your missed dose was due: Skip it entirely. Take your next dose on your regular day at your regular dose. Do not double up or take two injections to compensate.
Multiple missed doses: If you've missed two or more consecutive doses, contact your prescriber. They may want to reassess your titration level, especially if you were in the escalation phase. Restarting at a lower dose after a gap is common and reduces the risk of severe GI side effects from re-exposure at a higher level.
During titration: A missed dose during the escalation phase can disrupt the adaptation process. If you miss a dose at your current titration step, your prescriber may extend that step by an additional week or two rather than moving you up on schedule. The goal is adequate time at each dose, not adherence to a calendar.
Managing Side Effects During Titration
Gastrointestinal side effects are the primary challenge during dose escalation. Here's what the data shows and what helps:
Nausea: The most commonly reported side effect, affecting roughly 12-18% of patients in clinical trials depending on dose. It's typically worst in the first 1-2 weeks at a new dose level and then diminishes. Eating smaller meals, avoiding high-fat foods, and staying hydrated all help. If nausea at a new dose level doesn't improve after 2-3 weeks, tell your prescriber — they may extend your time at that dose before the next increase.
Diarrhea: Reported by approximately 12-17% of patients. Usually transient. Severe or persistent diarrhea warrants a call to your provider, particularly because of dehydration risk.
Decreased appetite: This is both a side effect and the mechanism of action. If it becomes so extreme that you're unable to eat adequate nutrition (protein, hydration), that's a signal your dose may be too aggressive for your current tolerance.
Constipation: Affects about 6-8% of patients. Adequate water intake and fiber can help. If it becomes uncomfortable, your provider has options.
Injection site reactions: Mild redness or itching at the injection site occurs in about 3-5% of patients and typically resolves within a few days.
The "Stay or Go Up" Decision
At each titration step, you and your prescriber evaluate: are you tolerating this dose? Are you seeing clinical results? Is there reason to increase?
Not every patient goes to 15 mg. If you're achieving your A1c targets or weight loss goals at 7.5 mg with manageable side effects, there may be no clinical reason to increase. Higher doses produce greater average effects in trials, but individual response varies, and the best dose is the one you can sustain long-term.
Why Tracking Titration Matters
Titration creates a particular tracking challenge because your dose changes on a schedule, your side effect profile shifts at each level, and the decisions about whether to escalate depend on data you can only have if you've been recording it.
Things worth logging at each dose step:
- Injection date and dose level — confirms you're on schedule
- Injection site — supports rotation (see our GLP-1 injection site rotation guide)
- GI symptoms and severity — shows your prescriber the adaptation curve at each dose
- Appetite and eating patterns — useful for nutritional monitoring
- Weight — weekly weigh-ins at the same time of day on the same scale, understood as a trend rather than individual data points
Done Dose tracks all of this in one place, including dose-level history so you and your provider can see exactly how long you spent at each titration step and what your experience was at each level. When it's time to decide whether to escalate, skip, or hold, the data is there instead of a hazy recollection of "I think the nausea was pretty bad around week 7."
Titration Timeline: Setting Realistic Expectations
If you're starting Mounjaro for weight management, here's a realistic timeline of what to expect:
Weeks 1-4 (2.5 mg): Minimal weight change. Possible mild nausea. Appetite may decrease slightly. This is the adaptation phase.
Weeks 5-12 (5-7.5 mg): Appetite suppression becomes noticeable. Most people begin to see weight change. GI side effects may flare at each dose increase, then settle.
Weeks 13-20 (10-12.5 mg): Continued weight loss if it's occurring. This is where many patients find their maintenance dose. Side effects should be manageable if the titration has been well-paced.
Week 21+ (15 mg, if prescribed): Maximum dose effects. Clinical trials measured primary endpoints at 72 weeks, reflecting the fact that full results develop over many months.
The titration schedule means you won't be at your target dose for at least a month (if 5 mg) to five months (if 15 mg). Impatience is natural, but the structure protects you. Every dose level you tolerate well is a dose level you're more likely to sustain.
